Tailored transplant care in older adults shows promise
Deaths unrelated to disease relapse reached 6.3% at one year, compared with historical rates of 25%, in 32 patients aged 60 or older.
Our read
Interventions- Studied:
- Single-arm trial in 32 older patients undergoing their first alloHCT, median 28.1 months
- What changed:
- Deaths without disease relapse were lower: 6.3% at one year against historical rates of 25%
- The catch:
- Differences in other care could account for lower mortality than historical rates
- Why it’s aging research:
- It measures an outcome that worsens with age.
Editor of record: Boris Djordjevic · AgingResearch.News
Thirty-two patients aged 60 or older, with a median age of 69.3, underwent their first donor blood-forming cell transplant in a single-center phase II trial. Geriatric assessments guided pre-transplant treatment: robust patients received more intensive preparation, while vulnerable patients received less intensive preparation. A geriatrics team provided continued assessments and individualized care.
At one year, 6.3% had died without disease relapse, meeting the trial’s primary goal. The team reported no unexpected toxic effects attributed to the intervention. With median follow-up of 28.1 months, two-year overall survival was 72%, and 56% were alive without disease progression. Patient reports and objective measures of functioning were stable to improved six to 12 months after transplantation.
Why it matters
For older adults considering potentially curative transplants, the question is whether identifying vulnerabilities and tailoring ongoing care can improve both survival and functioning.
Caveats
The comparison used historical rates rather than a concurrent control group, so differences in patients or other care could account for the favorable results. The trial included only 32 patients at one center, all undergoing their first donor-cell transplant.
Comments
Be the first to comment.